Lemme claims that the product acts to promote GLP-1 production, reduce hunger and cravings, promote fat reduction and healthy weight management on the basis of three clinically-studied ingredients. If Lemme argues in a motion to dismiss or its Answer that the case should be barred because a private consumer cannot bring a lawsuit based on lack of adequate substantiation, the plaintiffs may argue that clinically studied implies clinically proven or clinically shown and, therefore, may convey that the product has the level of support touted in the advertising
It may help in managing free radical damage
Glucagon-Like Peptide-1 Receptor Agonists to Expand the Healthy Lifespan: Current and Future Potentials
Serious risks include potential increased risk of pancreatitis, gallbladder disease, and thyroid tumors in animal studies
Key Players in the GLP-1 Diabetes Treatment Drugs Market Eli Lilly Sanofi Novo Nordisk Hanmi Pharmaceutical Co Boehringer Ingelheim AstraZeneca Pfizer Inc Teva Pharmaceutical Industries Ltd GlaxoSmithKline (GSK) Ganli Pharmaceuticals Tonghua Dongbao Shanghai Renhui Biopharmaceuticals Co., Ltd